In the News
“A huge challenge for healthcare leaders is that they are being asked to sustain high performance inside systems…
Will GLP-1 pills change how employers approach coverage? It’s an important question, but the answer isn't so straightforward.
On the surface, lower GLP-1 prices should make these therapies easier to manage. But as Rae McMahan, SVP…
Even with increased availability, access to GLP-1 therapies can be challenging for employers and healthcare consumers due to…
Access is the new standard – and with partners like Ilant Health, Prescryptive is delivering it. Our collaboration…
Prescription drug costs are among the fastest-growing and most unpredictable healthcare expenses employers face. According to recent data,…
Glucagon-like peptide-1 (GLP-1) therapies are reshaping care for diabetes, obesity, and cardiometabolic health. Yet with their rapid rise…
As healthcare costs continue to burden small businesses, voluntary prescription plans could be a compelling solution for employers…
Prescryptive’s SVP of Payer Solutions, Rae McMahan, offers timely insights in her new article in BenefitsPRO, “With tariffs in…
In a recent Newsweek article highlighting the surge of U.S. store closures—5,822 so far this year, compared to…
In a recent Drug Topics live interview at NCPDP 2025, Prescryptive’s SVP of Provider Solutions, Miranda Rochol, shares…
Miranda Rochol, Senior Vice President at Prescryptive Health, is leading the charge in transforming how healthcare consumers interact…